ArticleActa neurochirurgica2026
Endoscopic resection of knosp grade 0-2 growth hormone-secreting pituitary adenomas with routine medial cavernous sinus wall excision.
Article in Acta neurochirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopic surgical resection is gold standard treatment for growth hormone-secreting pituitary adenomas (GH-PA). However, biochemical remission rates are only approximately 40-60% after adenoma resection. Emerging evidence suggests that invasion of the medial cavernous sinus wall may contribute to persistent disease, even in low Knosp grade GH-PAs. This single-center study evaluated clinical and biochemical outcome of GH-PA resection with medial cavernous sinus wall excision-an approach that has demonstrated promising results internationally. We compared these data with two historical cohorts from our own institution operated microscopically and endoscopically respectively.
methodsFourteen patients had endoscopic GH-PA resection with medial cavernous sinus wall excision (ERA + MCS) at Odense University Hospital during 2023 to 2025. All procedures were performed by a specialized skull base surgical team. Patient outcomes were assessed based on radiologic and biochemical remission at 3 and 6 months and perioperative complications were evaluated. The historical cohorts comprised of 29 patients operated microscopically with adenoma resection (MRA) and 16 patients operated endoscopically with adenoma resection without excision of the medial cavernous sinus wall (ERA-MCS). In all three cohorts the surgeries were primary.
resultsEndoscopic GH-PA resection with medial cavernous sinus wall excision resulted in complete 6 months biochemical and 3 months radiological remission in 86% of primary GH-secreting adenoma (Knosp grade 0-2). No intraoperative complications were observed, and early postoperative complications were minimal, with transient syndrome of inappropriate antidiuretic hormone secretion occurring in two patients (14%). Remission rates in the historic cohorts, were 31% (MRA) and 38% (ERA-MCS), respectively.
conclusionOur data confirms that endoscopic resection of GH-PAs with routine medial cavernous sinus wall excision is a safe and effective surgical approach yielding high remission rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.